Skip to main content
International Journal of Oncology logoLink to International Journal of Oncology
. 2019 Mar 19;54(5):1503–1510. doi: 10.3892/ijo.2019.4755

Human papillomavirus infection and ocular surface disease (Review)

Aikaterini K Chalkia 1, Georgios Bontzos 2, Demetrios A Spandidos 3, Efstathios T Detorakis 1,
PMCID: PMC6438422  PMID: 30896784

Abstract

Human papillomavirus (HPV) infection has been implicated as a primary cause of lesions in the anogenital region, skin, oropharynx and respiratory tract. Additionally, the role of HPV in the pathogenesis of ocular surface disease has also been extensively studied. Conjunctival papilloma development has been strongly associated with the HPV infection of certain subtypes. On the other hand, the role of HPV in conjunctival pterygium, conjunctival intraepithelial neoplasia (CIN) and ocular surface squamous neoplasia (OSSN) remains controversial. Genetic predisposition and environmental factor is important in HPV hosts as regards the pathogenesis of ocular surface disease. Several studies have indicate a synergic role of HPV with ultraviolet radiation in pterygium establishment. A higher recurrence risk rate and more aggressive disease of ophthalmic pterygium is observed in cases of HPV infection. The purpose of this review was to provide a systematic review of the literature and to assist in a better understanding of the role of HPV in ocular surface disease.

Keywords: human papillomavirus, virus, conjunctiva, papilloma, neoplasia

1. Introduction

Papillomaviruses (HPV) belong to the virus family of Papovaviridae. The papillomaviruses are highly host species-specific and tissue-restricted, and present epithelial tropism. More than 100 genotypes of human papillomaviruses have been fully sequenced, and more HPV types are continuously being found (1,2).

All recognized viruses require terminal differentiation for replication and virion production. HPVs cause a wide range of diseases from benign lesions to invasive tumors (3). They are grouped in 3 groups as follows: Cutaneous, mucocutaneous and associated with the autosomal recessive epidermodysplasia verruciformis (EV). According to their propensity for malignant progression in the cervix, mucocutaneous HPVs have been divided into low- and high-risk types (4).

Papillomaviruses are small, non-enveloped viruses with icosahedral symmetry and contain a double-strained circular DNA with approximately 8 open reading frames which are divided into 3 functional regions: The early (E) region encoding proteins E1- E7 responsible for viral replication, the late (L) region encoding structural proteins L1-L2, and the long control region (LCR) responsible for transcription and replication (5,6). Only the E6 and E7 proteins of high-risk HPV strains present transforming properties by interacting with the tumor suppressor genes p53 and with the retinoblastoma family of proteins pRb, involved in controlling cell proliferation (7,8). The viral proteins may also contribute to potentially higher number of abnormalities in the cell genetic material (9).

In recent years, HPV has been associated with benign and malignant lesions of not only the anogenital region, but also of the skin, oropharynx, respiratory tract and ocular surface with variation of different genotypes tropism in the various anatomical sites (10-12). The epithelium of the ocular surface is exposed to the environment and therefore it is susceptible to infections, particularly in cases when protective barriers of mucin, tears and superficial cellular layer are compromised. HPV has mainly been shown to be involved in the pathogenesis of ocular surface diseases, such as conjunctival papillomas, papillomas and carcinomas of the lacrimal sac, conjunctival intraepithelial neoplasia (CIN), ocular surface squamous neoplasia (OSSN) and conjunctival pterygium and even squamous cell carcinoma of the conjunctiva (SCCC) (12-14).

2. Data collection methods

For this review article, a thorough search on MEDLINE (through PubMed), EMBASE (through OVID) and SCOPUS was performed, from inception to February, 2019, in order to identify studies addressing the association between infection with HPV and ocular surface disease.

3. HPV detection in ophthalmic pterygium

Conjunctival pterygia are fibrovascular lesions of the bulbar conjunctiva, that can display an aggressive clinical behavior and, occasionally, threaten vision. They represent a proliferative disorder of the conjunctiva, characterized by the overgrowth of altered limbal cells centripetally towards the cornea in a wing-shaped manner. In advanced stages, they present Bowman's layer dissolution, epithelial and mesenchymal transition and stromal inflammation, neovascularization and matrix remodeling under the action of cytokines, growth factors matrix metalloproteinases and vascular endothelial growth factors. They have a predilection for nasal limbus and their growth can obscure the visual axis, and can cause irregular astigmatism and chronic inflammation (15). Its pathogenesis is considered a multifactorial process where ultraviolet (UV) radiation (16) and other environmental factors, genetic predisposition and oncogenic viruses may play a role (17). Increased UV-associated oxidative stress has been reported in pterygium, compared with normal conjunctiva, leading to the induction of proteins, such as survivin (18). The latter has been associated with DNA oxidation and the downregulation of p53 (18). Detorakis et al (19) previously identified potential viral co-morbidity in pterygium development and proposed a 'two-hit' theory for its establishment. The first hit is a damaging reaction mediated by UV radiation exposure that leads to genetic alterations or mutations, and the second hit is an oncogenic event mediated by viral infection in the compromised ocular barriers.

HPV has been extensively studied as a possible pathogenetic co-factor; however controversy exists between different studies (Table I). In their studies, McDonnell et al (20), Dushku et al (22), Chen et al (26), Schellini et al (28), Kuo et al (29), Otlu et al (32), Guthoff et al (34) and Hamed-Azzam et al (38) did not detect HPV in pterygia, while Sjo et al (13), Takamura et al (30) and Hsaio et al (36) noted a very low prevalence of the virus ranging from 3-4,8%.

Table I.

HPV in ophthalmic pterygium.

Author (Refs.) Date of publication HPV prevalence HPV type Country of the study Method of detection Sample size
McDonell et al (20) 1992 0% - USA PCR 6
Varinli et al (21) 1994 64% - Turkey IHC 25
Dushku et al (22) 1999 0% - USA PCR 13
Detorakis et al (23) 2001 24% 18 Greece PCR 50
Gallagher et al (24) 2001 50% 6, 11, 16 UK PCR 10
Piras et al (25) 2003 100%
21%
Types 52, 54, candHPV90 Italy/Equador PCR, sequencing 41
Chen et al (26) 2003 0% - Taiwan PCR 65
Ateenyi-Agaba et al (27) 2004 50% 11, 37 Uganda PCR, Southern blotting 10
Schellini et al (28) 2006 0% - Brazil PCR 36
Kuo et al (29) 2006 0% - Taiwan PCR 4
Sjö et al (13) 2007 4.4% 6 Denmark PCR, ISH 90
Takamura et al (30) 2008 4.8% - Japan PCR-HC II 42
Rodrigues et al (31) 2008 58.3% 1, 2, 16 Brazil PCR 36
Otlu et al (32) 2009 0% - Turkey Real-time PCR 40
Tsai et al (33) 2009 24% 16, 18 Taiwan Nested PCR 129
Guthoff et al (34) 2009 0% - Germany PCR, IHC
Piecyk-Sidor et al (35) 2009 27.6% 5, 6, 11, 16, 18, 31, 52, 59 Poland PCR 58
Hsiao et al (36) 2010 3% 18 Taiwan PCR, ISH 65
Chong et al (37) 2014 64.4% 16, 18, 58, 59 Malaysia Nested PCR 45
Hamed-Azzam et al (38) 2016 0% - Israel IHC 100
Chalkia et al (39) 2018 42.86% 33, 39, 45, 56, 59, 66 Greece Real-time PCR 21

HPV, human papillomavirus; IHC, immunohistochemistry; ISH, in situ hybridization; HC II, hybrid capture II.

On the contrary, a number of previously published studies have successfully detected HPV (21,23-25,27,31,33,35,37,39) The average HPV prevalence in human pterygium was found to be 18.6% (range 0-100%) (40). The lack of consensus between studies could reflect differences in methodology and sampling. Piras et al (25) proposed that geographic differences in the prevalence of the virus in the various countries may explain these findings, supporting its multifactorial pathogenesis.

The diagnosis of viral infection is based on the detection of HPV-DNA. The application of various detection techniques with varied sensitivity and specificity can significantly compromise the results (41). HPV-DNA can be directly isolated from a biopsy specimen with in situ hybridization (ISH), Southern blotting and dot blot hybridization. These techniques however, are laborious and lack sensitivity. By contrast, polymerase chain reaction (PCR) is highly associated with false-positive results due to its high sensitivity (42). Real-time PCR permits the rapid detection and quantification of the viral load (42). Reverse transcriptase-PCR is a qualitative assay that permits the identification of viral gene expression with the use of reverse transcriptase (42). A combination of the previous techniques can be applied in order to acquire qualitative and qualitative information of viral gene expression.

Pterygium treatment is based on surgical excision and the topical use of antimetabolites, such as mitomycin C (MMC) or 5-fluorouracil. Several surgical techniques have been described, such as bare sclera closure and sliding conjunctival flaps (43). The additional use of conjunctival autografts or amniotic membrane grafts, has significantly lowered the need for repetitive surgery, although recurrences may still occur (44).

4. HPV detection in conjunctival papilloma

Conjunctival papillomas represent one of the most common benign tumors of the squamous epithelium of the conjunctiva. They may display dysplasia, but rarely undergo malignant transformation (45). Despite their tendency to recur following surgical excision, spontaneous regression is possible. According to their growth pattern, conjunctival papillomas may present as exophytic, mixed or more rarely inverted. The exophytic growth pattern may be sessile or pedunculated (12). Although they can appear in both children and adults (46), they most frequently occur in adults aged 20-39 years, which also corresponds to the peak age of genital HPV infection in sexually active adults. Papillomas seem to appear with a male preponderance and their incidence declines with increasing age. They are usually detected medially and inferiorly on the conjunctiva (45).

Their pathogenetic role has not been fully clarified. HPV infection by auto-inoculation from contaminated fingers has been strongly associated with their development. Fetal passage through an HPV-infected birth canal may explain the presence of conjunctival papilloma in children. Several studies have investigated the role of HPV in the pathogenesis of conjunctival papilloma (Table II). In the majority of these cases, the low-risk HPV types 6 and 11, typically found in condylomata accuminata, are predominant among HPV-infected conjunctival papillomas with an incidence varying from 50-100%. Egbert and Kersten (61) also refer the detection of HPV 6 and 11 in a conjunctival papilloma of an infant whose mother suffered from vulvar HPV infection during pregnancy, indicating a possible vertical transmission during delivery. The detection of low-risk HPV types in conjunctival papillomas may explain the benign nature of these lesions. In addition, HPV infection has been also detected in epithelial lacrimal sac papillomas and carcinomas. The tear flow on an HPV infected conjunctiva may be responsible for the development of such lesions.

Table II.

HPV in conjuctival papilloma.

Author (Refs.) Date of publication HPV prevalence HPV types Method of detection Sample size
Lass et al (47) 1983 50% 11 SB 2
Naghashfar et al (48) 1986 0% - SB/ISH 1
McDonnell et al (49) 1987 65% 6, 11 ISH 23
Mäntyjärvi et al (50) 1989 0% - ISH 1
Fierlbeck et al (51) 1990 0% - ISH 1
Mincione et al (52) 1992 50% 6, 11 ISH 4
Saegusa et al (53) 1995 100% 16 PCR 5
Michel et al (54) 1996 0% - ISH 1
Nakamura et al (55) 1997 50% 6 PCR 8
Assadoullina et al (56) 2000 0% - PCR 1
Sjo et al (57) 2001 92% 6, 11, 16 PCR 52
Minchiotti et al (58) 2006 100% 11 PCR 4
Sjö et al (59) 2007 81% 6, 11, 45 PCR 106
Takamura et al (30) 2008 100% - PCR/HC-II 8
Annadanam et al (60) 2017 100% 6, 11 ISH 1

HPV, human papillomavirus; SB, Southern blotting; ISH, in situ hybridization; HC II, hybrid capture II.

Treatment options of conjunctival papillomas include mainly surgical excision, cryotherapy and carbon dioxide laser (62). Additionally, oral cimetidine, topical MMC and topical interferon-α have been implicated in the management of these benign lesions (63). However, despite the various therapies, the recurrence rate in conjunctival papilloma remains high (6-27%).

5. HPV detection in ocular surface squamous neoplasia

OSSN encompasses a wide range of conjunctival lesions that range histologically from dysplasia and carcinoma in situ, generally termed CIN, to invasive SCCC and is considered the most common ocular-surface malignancy (64). It involves more commonly the interpalpebral area, arising from the limbus and may extend to involve cornea (65). The incidence of OSSN varies widely with increased incidence in countries where HIV infection is an epidemic (66). In fact, immunosuppression due to HIV-infection has been strongly associasted with OSSN, as various studies have demonstrated a 10-fold increase for OSSN in these patients. Other risk factors associated with OSSN are an advanced age, the male sex, UV exposure, immunosuppression, atopic eczema and xeroderma pigmentosum (66,67). Conjunctival SCC represents the most severe form of OSSN, which if left untreated, can result in mortality (68). Metastasis to lymph nodes is common; thus, aggressive treatment with enucleation or exenteration should be considered (69).

A number of studies have been conducted in order to identify the presence of HPV in OSSN (Table III). However, the reported presence of the virus varies widely with a range from 0-100%. From the studies reported to date in Table III, an average prevalence rate of 33.8% (range, 0-100%) has been observed. It should also be noted that in the majority of these studies, the HIV status of the patients has not been disclosed, leaving the role of HIV as enhancer or confounder of HPV carcinogenicity in OSSN unclear. In a number of studies, mucosal, mainly high risk types 16 and 18 have been detected. Scott et al (75) isolated HPV16 and mRNA corresponding to the E6 region in CIN specimens. Notably, Ateenyi-Agaba et al (14) detected cutaneous HPV types in nearly half of OSSN cases in HIV-positive patients, but rarely in HIV-negative patients, and thus no association was found with mucosal types in both groups. Chauhan et al (84) also reported an improved disease-free survival of patients with HPV-infected OSSN. On the other hand, De Koning et al (81) noted a low prevalence of cutaneous HPV cases and no evidence of association of mucosal HPV types with OSSN. Tornesello et al (79) also noted an absence of high-risk types and low detection of EV-related types in their study and yet, another study (74) did not note significant correlation between abnormal p53 gene-product expression in OSSN and HPV infection. These discrepancies between the different studies render the role of HPV in OSSN uncertain.

Table III.

HPV in OSSN.

Author (Refs.) Date of publication HPV prevalence HPV types Method of detection Sample size HIV status
Lauer et al (70) 1990 80% 16, 18 PCR 5 -
Tuppurainen et al (71) 1992 0% - PCR/ISH 4 -
McDonnell et al (20) 1992 88% 16 PCR 42 -
Tabrizi et al (72) 1997 39% 6, 11, 16, 18 PCR 88 -
Karcioglu et al (73) 1997 55.6% 16,18 Nested PCR, SB 45 -
Dushku et al (22) 1999 0 - Nested PCR 8 -
Toth et al (74) 2000 22% 16, 18 PCR/IHC 23 -
Scott et al (75) 2002 100% 16, 18 PCR/ISH 10 -
Eng et al (76) 2002 0% - Nested PCR 20 -
Tulvatana et al (77) 2003 0% - PCR/dot hybridization 30 -
Ateenyi-Agaba et al (27) 2004 86% EV-HPV types PCR 21 -
Moubayed et al (78) 2004 93% 6, 11, 18 ISH immunomax 14 64,2%
Tornesello et al (79) 2006 19.8% 6, 18, EV-related HPVs, CJ198 PCR 86 65,1% (25% HPV+)
Kuo et al (29) 2006 100% 6, 11, 16, 18, 33, 37, 58, 72 Nested PCR 9 -
Sen et al (80) 2007 0% - IHC 30 -
De Koning et al (81) 2008 38% Genital (both high and low risk). 22% cutaneous types PCR 81 (48% HPV+)
Manderwad et al (82) 2009 0% - PCR/ISH-CARD 57 -
Guthoff et al (34) 2009 0% - PCR/IHC 31 No HIV patients
Ateenyi-Agaba et al (14) 2010 Mucosal HPV: 6,4% SCC; 7,7% dysplasia cutaneous HPV: 44,7% SCC; 41% dysplasia PCR 39 dysplasia 94 SCC Uncertain role of HIV
Asadi-Amoli et al (83) 2011 88% No type found Nested PCR 50 -
Chauhan et al (84) 2012 11% 16 PCR 64 -
Woods et al (85) 2013 6.5% 16 Nested PCR 50 -
Afrogheh et al (86) 2016 30% 16 IHC, ISH, PCR 43 ?

HPV, human papillomavirus; OSSN, ocular surface squamous neoplasia; ISH, in situ hybridization; CARD, catalyzed reporter deposition; IHC, immunohistochemistry; SCC, squamous cell carcinoma.

Margin-free excision remains the treatment of choice for OSSN. The additional use of topical mitomycin, 5-fluorouracil, interferon and cryotherapy and radiation may be used to reduce the risk of recurrence and metastasis (87).

6. Conclusions and future perspectives

HPV is a known cause of intraepithelial damage which leads to squamous neoplasms on mucosal surfaces (88). Many types of cervical carcinoma and precancerous lesions have been attributed to HPV infection. In addition, HPV has been linked with dysplastic and malignant squamous lesions of the oropharynx (89). The associatoin between HPV and squamous neoplasms of the ocular surface and the conjunctiva is not completely understood. It appears that the HPV genotype as well as the presence of associated risk factors play a significant role in lesion pathogenesis (13,45).

Koilocytosis is the histological hallmark of HPV infection (90). The koilocyte is a superficial or intermediate mature squamous cell characterized by perinuclear vacuolation, densely staining peripheral cytoplasm, and a nucleus with an undulating nuclear membrane and a rope-like chromatin pattern (91). Viral antigen has been demonstrated in nuclei of koilocytes using broad spectrum papillomavirus antibodies (47).

HPV has been identified in several lesions of the ocular surface. A strong association between HPV types 6 and 11 and conjunctival papilloma has been established (49,52,57,59,60). The varied percentages of papillomas associated with HPV presence could be attributed to differences in genetic predisposition, lifestyle and environmental exposure (73). In cases of pterygium, the association between the virus presence is not clear. Based on current data, HPV appears to function as a pathogenetic co-factor in addition to genetic factors like p53 gene mutation (92), as well as environmental factors, such as UV radiation and HIV co-infection (18) and chemical exposure (73). Despite the controversies in the literature, HPV infections seem to be a crucial co-morbidity in susceptible hosts (33). Frequent recurrences of a pterygium following excision may be associated with the presence of HPV (24). The proposed pathogenesis involves p53 inactivation (33).

While there is a strong association between HIV and the risk of OSSN (66), the role of HPV is less conclusive. Previous studies have suggested that only the cutaneous HPV subtype, and not the mucosal, is correlated with the presence of OSSN (14,81). Furthermore, older individuals seem to be more prone to the development of the described lesions (40).

The discrepancies in the reported results may be attributed to the selection bias of different regions (25) and the different methods for HPV isolation. While there is no gold standard for measuring HPV, PCR is generally considered to be the most sensitive method (76). It should also be noted that the newer HPV subtypes are continuously sequenced; thus, the range of possible genotype identification is incomplete. Some unknown types of HPV could be involved in the pterygium pathogenesis (93). Chalkia et al (39) described PCR-mediated exfoliative cytology as a valuable detection method for HPV in ophthalmic pterygium, while others have used exfoliative cytology for OSSN and conjunctival papilloma (94). The use of an easy-applicable, reliable and cost effective method may offer a more detailed investigation of the role of HPV in ocular surface, that may permit the use of topical antiviral treatment in HPV related ocular surface diseases. In fact, two recent studies (95,96) refer the efficient topical use of Cidofovir in OSSN. Cidofovir is a nucleoside analog with activity against a broad spectrum of DNA viruses. It has been used efficiently in squamous papilloma of the oropharynx, condylomata acuminata, molluscum contagiosum, and Kaposi's sarcoma (97,98). Finally, it would be of interest to evaluate the potential effect of HPV vaccination on the prevalence of these diseases in the future.

To conclude, HPV infection seems to play an important role in several aspects of ocular surface disease. Further research is required to elucidate the specific pathogenetic mechanisms of HPV in various ocular surface disease entities and findings may be clinically important in view of the potential development of targeted therapies or preventive measures, such as HPV vaccines.

Acknowledgments

Not applicable.

Abbreviations

HPV

human papillomavirus

CIN

conjunctival intraepithelial neoplasia

OSSN

ocular surface squamous neoplasia

SCCC

squamous cell carcinoma of the conjuctiva

UV

ultraviolet

MMC

mitomycin C

EV

Epidermodysplasia verruciformis

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

AKC was involved in the design of the study, and in the acquisition of data, drafting and writing of the manuscript. GB was involved in the acquisition and analysis of the data from studies to be included in this review, and in the drafting and writing of the manuscript. ETD and DAS were involved in the conception of the study, and in the revision of the manuscript. All authors have read and approved the final version.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that they have no competing interests.

References

  • 1.Bottalico D, Chen Z, Dunne A, Ostoloza J, McKinney S, Sun C, Schlecht NF, Fatahzadeh M, Herrero R, Schiffman M, et al. The oral cavity contains abundant known and novel human papilloma-viruses from the Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis. 2011;204:787–792. doi: 10.1093/infdis/jir383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Köhler A, Gottschling M, Manning K, Lehmann MD, Schulz E, Krüger-Corcoran D, Stockfleth E, Nindl I. Genomic characterization of ten novel cutaneous human papillomaviruses from keratotic lesions of immunosuppressed patients. J Gen Virol. 2011;92:1585–1594. doi: 10.1099/vir.0.030593-0. [DOI] [PubMed] [Google Scholar]
  • 3.Duensing S, Münger K. Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. Int J Cancer. 2004;109:157–162. doi: 10.1002/ijc.11691. [DOI] [PubMed] [Google Scholar]
  • 4.Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013;445:21–34. doi: 10.1016/j.virol.2013.06.007. [DOI] [PubMed] [Google Scholar]
  • 5.Mistry N, Wibom C, Evander M. Cutaneous and mucosal human papillomaviruses differ in net surface charge, potential impact on tropism. Virol J. 2008;5:118. doi: 10.1186/1743-422X-5-118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Graham SV. Human papillomavirus: Gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future Microbiol. 2010;5:1493–1506. doi: 10.2217/fmb.10.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci. 2006;11:2286–2302. doi: 10.2741/1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78:11451–11460. doi: 10.1128/JVI.78.21.11451-11460.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Nair S, Pillai MR. Human papillomavirus and disease mechanisms: Relevance to oral and cervical cancers. Oral Dis. 2005;11:350–359. doi: 10.1111/j.1601-0825.2005.01127.x. [DOI] [PubMed] [Google Scholar]
  • 10.Ljubojevic S, Skerlev M. HPV-associated diseases. Clin Dermatol. 2014;32:227–234. doi: 10.1016/j.clindermatol.2013.08.007. [DOI] [PubMed] [Google Scholar]
  • 11.Gélinas JF, Manoukian J, Côté A. Lung involvement in juvenile onset recurrent respiratory papillomatosis: A systematic review of the literature. Int J Pediatr Otorhinolaryngol. 2008;72:433–452. doi: 10.1016/j.ijporl.2007.12.003. [DOI] [PubMed] [Google Scholar]
  • 12.Verma V, Shen D, Sieving PC, Chan CC. The role of infectious agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol. 2008;53:312–331. doi: 10.1016/j.survophthal.2008.04.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Sjö NC, von Buchwald C, Prause JU, Norrild B, Vinding T, Heegaard S. Human papillomavirus and pterygium. Is the virus a risk factor? Br J Ophthalmol. 2007;91:1016–1018. doi: 10.1136/bjo.2006.108829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ateenyi-Agaba C, Franceschi S, Wabwire-Mangen F, Arslan A, Othieno E, Binta-Kahwa J, van Doorn LJ, Kleter B, Quint W, Weiderpass E. Human papillomavirus infection and squamous cell carcinoma of the conjunctiva. Br J Cancer. 2010;102:262–267. doi: 10.1038/sj.bjc.6605466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hilgers JH. Pterygium: Its incidence, heredity and etiology. Am J Ophthalmol. 1960;50:635–644. doi: 10.1016/0002-9394(60)90245-2. [DOI] [PubMed] [Google Scholar]
  • 16.Zhou WP, Zhu YF, Zhang B, Qiu WY, Yao YF. The role of ultraviolet radiation in the pathogenesis of pterygia (Review) Mol Med Rep. 2016;14:3–15. doi: 10.3892/mmr.2016.5223. [DOI] [PubMed] [Google Scholar]
  • 17.Cárdenas-Cantú E, Zavala J, Valenzuela J, Valdez-García JE. Molecular basis of pterygium development. Semin Ophthalmol. 2016;31:567–583. doi: 10.3109/08820538.2014.971822. [DOI] [PubMed] [Google Scholar]
  • 18.Maxia C, Perra MT, Demurtas P, Minerba L, Murtas D, Piras F, Corbu A, Gotuzzo DC, Cabrera RG, Ribatti D, et al. Expression of survivin protein in pterygium and relationship with oxidative DNA damage. J Cell Mol Med. 2008;12:2372–2380. doi: 10.1111/j.1582-4934.2008.00256.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Detorakis ET, Drakonaki EE, Spandidos DA. Molecular genetic alterations and viral presence in ophthalmic pterygium. Int J Mol Med. 2000;6:35–41. [PubMed] [Google Scholar]
  • 20.McDonnell JM, McDonnell PJ, Sun YY. Human papillomavirus DNA in tissues and ocular surface swabs of patients with conjunctival epithelial neoplasia. Invest Ophthalmol Vis Sci. 1992;33:184–189. [PubMed] [Google Scholar]
  • 21.Varinli S, Varinli I, Köksal Erkisi M, Doran F. Human papillomavirus in pterygium. Cent Afr J Med. 1994;40:24–26. [PubMed] [Google Scholar]
  • 22.Dushku N, Hatcher SL, Albert DM, Reid TW. p53 expression and relation to human papillomavirus infection in pingueculae, pterygia, and limbal tumors. Arch Ophthalmol. 1999;117:1593–1599. doi: 10.1001/archopht.117.12.1593. [DOI] [PubMed] [Google Scholar]
  • 23.Detorakis ET, Sourvinos G, Spandidos DA. Detection of herpes simplex virus and human papilloma virus in ophthalmic pterygium. Cornea. 2001;20:164–167. doi: 10.1097/00003226-200103000-00010. [DOI] [PubMed] [Google Scholar]
  • 24.Gallagher MJ, Giannoudis A, Herrington CS, Hiscott P. Human papillomavirus in pterygium. Br J Ophthalmol. 2001;85:782–784. doi: 10.1136/bjo.85.7.782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Piras F, Moore PS, Ugalde J, Perra MT, Scarpa A, Sirigu P. Detection of human papillomavirus DNA in pterygia from different geographical regions. Br J Ophthalmol. 2003;87:864–866. doi: 10.1136/bjo.87.7.864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Chen KH, Hsu WM, Cheng CC, Li YS. Lack of human papillomavirus in pterygium of Chinese patients from Taiwan. Br J Ophthalmol. 2003;87:1046–1048. doi: 10.1136/bjo.87.8.1046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ateenyi-Agaba C, Weiderpass E, Smet A, Dong W, Dai M, Kahwa B, Wabinga H, Katongole-Mbidde E, Franceschi S, Tommasino M. Epidermodysplasia verruciformis human papillomavirus types and carcinoma of the conjunctiva: A pilot study. Br J Cancer. 2004;90:1777–1779. doi: 10.1038/sj.bjc.6601743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Schellini SA, Hoyama E, Shiratori CA, Sakamoto RH, Candeias JM. Lack of papillomavirus (HPV) in pterygia of a Brazilian sample. Arq Bras Oftalmol. 2006;69:519–521. doi: 10.1590/S0004-27492006000400012. [DOI] [PubMed] [Google Scholar]
  • 29.Kuo KT, Chang HC, Hsiao CH, Lin MC. Increased Ki-67 proliferative index and absence of P16INK4 in CIN-HPV related pathogenic pathways different from cervical squamous intraepi-thelial lesion. Br J Ophthalmol. 2006;90:894–899. doi: 10.1136/bjo.2005.086314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Takamura Y, Kubo E, Tsuzuki S, Akagi Y. Detection of human papillomavirus in pterygium and conjunctival papilloma by hybrid capture II and PCR assays. Eye (Lond) 2008;22:1442–1445. doi: 10.1038/eye.2008.176. [DOI] [PubMed] [Google Scholar]
  • 31.Rodrigues FW, Arruda JT, Silva RE, Moura KK. TP53 gene expression, codon 72 polymorphism and human papillomavirus DNA associated with pterygium. Genet Mol Res. 2008;7:1251–1258. doi: 10.4238/vol7-4gmr528. [DOI] [PubMed] [Google Scholar]
  • 32.Otlu B, Emre S, Turkcuoglu P, Doganay S, Durmaz R. Investigation of human papillomavirus and Epstein-Barr virus DNAs in pterygium tissue. Eur J Ophthalmol. 2009;19:175–179. doi: 10.1177/112067210901900201. [DOI] [PubMed] [Google Scholar]
  • 33.Tsai YY, Chang CC, Chiang CC, Yeh KT, Chen PL, Chang CH, Chou MC, Lee H, Cheng YW. HPV infection and p53 inactivation in pterygium. Mol Vis. 2009;15:1092–1097. [PMC free article] [PubMed] [Google Scholar]
  • 34.Guthoff R, Marx A, Stroebel P. No evidence for a pathogenic role of human papillomavirus infection in ocular surface squamous neoplasia in Germany. Curr Eye Res. 2009;34:666–671. doi: 10.1080/02713680903007162. [DOI] [PubMed] [Google Scholar]
  • 35.Piecyk-Sidor M, Polz-Dacewicz M, Zagórski Z, Zarnowski T. Occurrence of human papillomavirus in pterygia. Acta Ophthalmol. 2009;87:890–895. doi: 10.1111/j.1755-3768.2008.01372.x. [DOI] [PubMed] [Google Scholar]
  • 36.Hsiao CH, Lee BH, Ngan KW, Chuang WY, Yeung L, Yeh LK, Tan HY, Hui-Kang D, Lin KK. Presence of human papillomavirus in pterygium in Taiwan. Cornea. 2010;29:123–127. doi: 10.1097/ICO.0b013e3181afdb06. [DOI] [PubMed] [Google Scholar]
  • 37.Chong PP, Tung CH, Rahman NA, Yajima M, Chin FW, Yeng CL, Go ES, Chan CM, Yawata N, Yamamoto N. Prevalence and viral load of oncogenic human papillomavirus (HPV) in pterygia in multi-ethnic patients in the Malay Peninsula. Acta Ophthalmol. 2014;92:e569–e579. doi: 10.1111/aos.12427. [DOI] [PubMed] [Google Scholar]
  • 38.Hamed-Azzam S, Edison N, Briscoe D, Mukari A, Elmalah I. Identification of human papillomavirus in pterygium. Acta Ophthalmol. 2016;94:e195–e197. doi: 10.1111/aos.12729. [DOI] [PubMed] [Google Scholar]
  • 39.Chalkia AK, Derdas S, Bontzos G, Sourvinos G, Detorakis ET. Non-invasive detection of HPV DNA in exfoliative samples from ophthalmic pterygium: A feasibility study. Graefes Arch Clin Exp Ophthalmol. 2018;256:193–198. doi: 10.1007/s00417-017-3840-5. [DOI] [PubMed] [Google Scholar]
  • 40.Di Girolamo N. Association of human papilloma virus with pterygia and ocular-surface squamous neoplasia. Eye (Lond) 2012;26:202–211. doi: 10.1038/eye.2011.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Abreu AL, Souza RP, Gimenes F, Consolaro ME. A review of methods for detect human Papillomavirus infection. Virol J. 2012;9:262. doi: 10.1186/1743-422X-9-262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Mackay IM. Real-time PCR in the microbiology laboratory. Clin Microbiol Infect. 2004;10:190–212. doi: 10.1111/j.1198-743X.2004.00722.x. [DOI] [PubMed] [Google Scholar]
  • 43.Hirst LW. The treatment of pterygium. Surv Ophthalmol. 2003;48:145–180. doi: 10.1016/S0039-6257(02)00463-0. [DOI] [PubMed] [Google Scholar]
  • 44.Todani A, Melki SA. Pterygium: Current concepts in pathogenesis and treatment. Int Ophthalmol Clin. 2009;49:21–30. doi: 10.1097/IIO.0b013e3181924f62. [DOI] [PubMed] [Google Scholar]
  • 45.Sjö N, Heegaard S, Prause JU. Conjunctival papilloma. A histopathologically based retrospective study. Acta Ophthalmol Scand. 2000;78:663–666. doi: 10.1034/j.1600-0420.2000.078006663.x. [DOI] [PubMed] [Google Scholar]
  • 46.Elsas FJ, Green WR. Epibulbar tumors in childhood. Am J Ophthalmol. 1975;79:1001–1007. doi: 10.1016/0002-9394(75)90685-6. [DOI] [PubMed] [Google Scholar]
  • 47.Lass JH, Jenson AB, Papale JJ, Albert DM. Papillomavirus in human conjunctival papillomas. Am J Ophthalmol. 1983;95:364–368. doi: 10.1016/S0002-9394(14)78307-2. [DOI] [PubMed] [Google Scholar]
  • 48.Naghashfar Z, McDonnell PJ, McDonnell JM, Green WR, Shah KV. Genital tract papillomavirus type 6 in recurrent conjunctival papilloma. Arch Ophthalmol. 1986;104:1814–1815. doi: 10.1001/archopht.1986.01050240088046. [DOI] [PubMed] [Google Scholar]
  • 49.McDonnell PJ, McDonnell JM, Kessis T, Green WR, Shah KV. Detection of human papillomavirus type 6/11 DNA in conjunctival papillomas by in situ hybridization with radioactive probes. Hum Pathol. 1987;18:1115–1119. doi: 10.1016/S0046-8177(87)80378-7. [DOI] [PubMed] [Google Scholar]
  • 50.Mäntyjärvi M, Syrjänen S, Kaipiainen S, Mäntyjärvi R, Kahlos T, Syrjänen K. Detection of human papillomavirus type 11 DNA in a conjunctival squamous cell papilloma by in situ hybridization with biotinylated probes. Acta Ophthalmol (Copenh) 1989;67:425–429. doi: 10.1111/j.1755-3768.1989.tb01627.x. [DOI] [PubMed] [Google Scholar]
  • 51.Fierlbeck G, Rassner G, Thiel HJ, Pfister H. Virus-induced papilloma of the conjunctiva. Detection of HPV 6a DNA. Z Hautkr. 1990;65:497–499. In German. [PubMed] [Google Scholar]
  • 52.Mincione GP, Taddei GL, Wolovsky M, Calzolari A, Mincione F. Detection of human papillomavirus (HPV) DNA type 6/11 in a conjunctival papilloma by in situ hybridization with biotinylated probes. Pathologica. 1992;84:483–488. [PubMed] [Google Scholar]
  • 53.Saegusa M, Takano Y, Hashimura M, Okayasu I, Shiga J. HPV type 16 in conjunctival and junctional papilloma, dysplasia, and squamous cell carcinoma. J Clin Pathol. 1995;48:1106–1110. doi: 10.1136/jcp.48.12.1106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Michel JL, Guiguen Y, Léger F, Gain P, Valanconny C, Cambazard F. Human papillomavirus 6/11 in conjunctival papilloma. Ann Dermatol Venereol. 1996;123:90–92. In French. [PubMed] [Google Scholar]
  • 55.Nakamura Y, Mashima Y, Kameyama K, Mukai M, Oguchi Y. Detection of human papillomavirus infection in squamous tumours of the conjunctiva and lacrimal sac by immunohisto-chemistry, in situ hybridisation, and polymerase chain reaction. Br J Ophthalmol. 1997;81:308–313. doi: 10.1136/bjo.81.4.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Assadoullina A, Bialasiewicz AA, de Villiers EM, Richard G. Detection of HPV-20, HPV-23, and HPV-DL332 in a solitary eyelid syringoma. Am J Ophthalmol. 2000;129:99–101. doi: 10.1016/S0002-9394(99)00292-5. [DOI] [PubMed] [Google Scholar]
  • 57.Sjö NC, Heegaard S, Prause JU, von Buchwald C, Lindeberg H. Human papillomavirus in conjunctival papilloma. Br J Ophthalmol. 2001;85:785–787. doi: 10.1136/bjo.85.7.785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Minchiotti S, Masucci L, Serapiao Dos Santos M, Perrella E, Graffeo R, Lambiase A, Bonini S. Conjunctival papilloma and human papillomavirus: Identification of HPV types by PCR. Eur J Ophthalmol. 2006;16:473–477. doi: 10.1177/112067210601600320. [DOI] [PubMed] [Google Scholar]
  • 59.Sjö NC, von Buchwald C, Cassonnet P, Norrild B, Prause JU, Vinding T, Heegaard S. Human papillomavirus in normal conjunctival tissue and in conjunctival papilloma: Types and frequencies in a large series. Br J Ophthalmol. 2007;91:1014–1015. doi: 10.1136/bjo.2006.108811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Annadanam A, Vizcaino MA, Eberhart CG, Khurshid GS, Gupta P. Long standing exophytic conjunctival papilloma infected with human papillomavirus. J Eye Ophthalmol. 2017;4:1. doi: 10.7243/2055-2408-4-1. [DOI] [Google Scholar]
  • 61.Egbert JE, Kersten RC. Female genital tract papillomavirus in conjunctival papillomas of infancy. Am J Ophthalmol. 1997;123:551–552. doi: 10.1016/S0002-9394(14)70184-9. [DOI] [PubMed] [Google Scholar]
  • 62.Kalogeropoulos C, Koumpoulis I, Papadiotis E, Zioga A, Gkrepi K, Pappa C, Paschides C, Malamou-Mitsi V, Aspiotis M. Squamous cell papilloma of the conjunctiva due to human papillomavirus (HPV): Presentation of two cases and review of literature. Clin Ophthalmol. 2012;6:1553–1561. doi: 10.2147/OPTH.S34999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Shields CL, Shields JA. Tumors of the conjunctiva and cornea. Surv Ophthalmol. 2004;49:3–24. doi: 10.1016/j.survophthal.2003.10.008. [DOI] [PubMed] [Google Scholar]
  • 64.Lee GA, Hirst LW. Ocular surface squamous neoplasia. Surv Ophthalmol. 1995;39:429–450. doi: 10.1016/S0039-6257(05)80054-2. [DOI] [PubMed] [Google Scholar]
  • 65.Lee GA, Hirst LW. Retrospective study of ocular surface squamous neoplasia. Aust N Z J Ophthalmol. 1997;25:269–276. doi: 10.1111/j.1442-9071.1997.tb01514.x. [DOI] [PubMed] [Google Scholar]
  • 66.Gichuhi S, Sagoo MS, Weiss HA, Burton MJ. Epidemiology of ocular surface squamous neoplasia in Africa. Trop Med Int Health. 2013;18:1424–1443. doi: 10.1111/tmi.12203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Ahmed H, Hassan RY, Pindiga UH. Xeroderma pigmentosum in three consecutive siblings of a Nigerian family: Observations on oculocutaneous manifestations in black African children. Br J Ophthalmol. 2001;85:110–111. doi: 10.1136/bjo.85.1.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Ogun GO, Ogun OA, Bekibele CO, Akang EE. Intraepithelial and invasive squamous neoplasms of the conjunctiva in Ibadan, Nigeria: A clinicopathological study of 46 cases. Int Ophthalmol. 2009;29:401–409. doi: 10.1007/s10792-008-9257-8. [DOI] [PubMed] [Google Scholar]
  • 69.McKelvie PA, Daniell M, McNab A, Loughnan M, Santamaria JD. Squamous cell carcinoma of the conjunctiva: A series of 26 cases. Br J Ophthalmol. 2002;86:168–173. doi: 10.1136/bjo.86.2.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Lauer SA, Malter JS, Meier JR. Human papillomavirus type 18 in conjunctival intraepithelial neoplasia. Am J Ophthalmol. 1990;110:23–27. doi: 10.1016/S0002-9394(14)76932-6. [DOI] [PubMed] [Google Scholar]
  • 71.Tuppurainen K, Raninen A, Kosunen O, Kankkunen JP, Kellokoski J, Syrjänen S, Mäntyjärvi M, Syrjänen K. Squamous cell carcinoma of the conjunctiva. Failure to demonstrate HPV DNA by in situ hybridization and polymerase chain reaction. Acta Ophthalmol (Copenh) 1992;70:248–254. doi: 10.1111/j.1755-3768.1992.tb04132.x. [DOI] [PubMed] [Google Scholar]
  • 72.Tabrizi SN, McCurrach FE, Drewe RH, Borg AJ, Garland SM, Taylor HR. Human papillomavirus in corneal and conjunctival carcinoma. Aust N Z J Ophthalmol. 1997;25:211–215. doi: 10.1111/j.1442-9071.1997.tb01394.x. [DOI] [PubMed] [Google Scholar]
  • 73.Karcioglu ZA, Issa TM. Human papilloma virus in neoplastic and non-neoplastic conditions of the external eye. Br J Ophthalmol. 1997;81:595–598. doi: 10.1136/bjo.81.7.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Toth J, Karcioglu ZA, Moshfeghi AA, Issa TM, Al-Ma'ani JR, Patel KV. The relationship between human papillomavirus and p53 gene in conjunctival squamous cell carcinoma. Cornea. 2000;19:159–162. doi: 10.1097/00003226-200003000-00007. [DOI] [PubMed] [Google Scholar]
  • 75.Scott IU, Karp CL, Nuovo GJ. Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia. Ophthalmology. 2002;109:542–547. doi: 10.1016/S0161-6420(01)00991-5. [DOI] [PubMed] [Google Scholar]
  • 76.Eng HL, Lin TM, Chen SY, Wu SM, Chen WJ. Failure to detect human papillomavirus DNA in malignant epithelial neoplasms of conjunctiva by polymerase chain reaction. Am J Clin Pathol. 2002;117:429–436. doi: 10.1309/RVUP-QMU3-5X6W-3CQ1. [DOI] [PubMed] [Google Scholar]
  • 77.Tulvatana W, Bhattarakosol P, Sansopha L, Sipiyarak W, Kowitdamrong E, Paisuntornsug T, Karnsawai S. Risk factors for conjunctival squamous cell neoplasia: A matched case-control study. Br J Ophthalmol. 2003;87:396–398. doi: 10.1136/bjo.87.4.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Moubayed P, Mwakyoma H, Schneider DT. High frequency of human papillomavirus 6/11, 16, and 18 infections in precancerous lesions and squamous cell carcinoma of the conjunctiva in subtropical Tanzania. Am J Clin Pathol. 2004;122:938–943. doi: 10.1309/T189UWWVB71M9VRC. [DOI] [PubMed] [Google Scholar]
  • 79.Tornesello ML, Duraturo ML, Waddell KM, Biryahwaho B, Downing R, Balinandi S, Lucas SB, Buonaguro L, Buonaguro FM. Evaluating the role of human papillomaviruses in conjunctival neoplasia. Br J Cancer. 2006;94:446–449. doi: 10.1038/sj.bjc.6602921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Sen S, Sharma A, Panda A. Immunohistochemical localization of human papilloma virus in conjunctival neoplasias: A retrospective study. Indian J Ophthalmol. 2007;55:361–363. doi: 10.4103/0301-4738.33822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.de Koning MN, Waddell K, Magyezi J, Purdie K, Proby C, Harwood C, Lucas S, Downing R, Quint WG, Newton R. Genital and cutaneous human papillomavirus (HPV) types in relation to conjunctival squamous cell neoplasia: A case-control study in Uganda. Infect Agent Cancer. 2008;3:12. doi: 10.1186/1750-9378-3-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Manderwad GP, Kannabiran C, Honavar SG, Vemuganti GK. Lack of association of high-risk human papillomavirus in ocular surface squamous neoplasia in India. Arch Pathol Lab Med. 2009;133:1246–1250. doi: 10.5858/133.8.1246. [DOI] [PubMed] [Google Scholar]
  • 83.Asadi-Amoli F, Heidari AB, Jahanzad I, Jabbarvand M. Detection of human papillomavirus in squamous cell carcinoma of conjunctiva by nested PCR: A case control study in Iran. Acta Med Iran. 2011;49:707–714. [PubMed] [Google Scholar]
  • 84.Chauhan S, Sen S, Sharma A, Dar L, Kashyap S, Kumar P, Bajaj MS, Tandon R. Human papillomavirus: A predictor of better survival in ocular surface squamous neoplasia patients. Br J Ophthalmol. 2012;96:1517–1521. doi: 10.1136/bjophthalmol-2012-301907. [DOI] [PubMed] [Google Scholar]
  • 85.Woods M, Chow S, Heng B, Glenn W, Whitaker N, Waring D, Iwasenko J, Rawlinson W, Coroneo MT, Wakefield D, et al. Detecting human papillomavirus in ocular surface diseases. Invest Ophthalmol Vis Sci. 2013;54:8069–8078. doi: 10.1167/iovs.13-13140. [DOI] [PubMed] [Google Scholar]
  • 86.Afrogheh AH, Jakobiec FA, Hammon R, Grossniklaus HE, Rocco J, Lindeman NI, Sadow PM, Faquin WC. Evaluation for high-risk HPV in squamous cell carcinomas and precursor lesions arising in the conjunctiva and lacrimal sac. Am J Surg Pathol. 2016;40:519–528. doi: 10.1097/PAS.0000000000000581. [DOI] [PubMed] [Google Scholar]
  • 87.Yin VT, Merritt HA, Sniegowski M, Esmaeli B. Eyelid and ocular surface carcinoma: Diagnosis and management. Clin Dermatol. 2015;33:159–169. doi: 10.1016/j.clindermatol.2014.10.008. [DOI] [PubMed] [Google Scholar]
  • 88.Hoffmann M, Ihloff AS, Görögh T, Weise JB, Fazel A, Krams M, Rittgen W, Schwarz E, Kahn T. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer. 2010;127:1595–1602. doi: 10.1002/ijc.25174. [DOI] [PubMed] [Google Scholar]
  • 89.Quiroga-Garza G, Zhou H, Mody DR, Schwartz MR, Ge Y. Unexpected high prevalence of HPV 90 infection in an under-served population: Is it really a low-risk genotype? Arch Pathol Lab Med. 2013;137:1569–1573. doi: 10.5858/arpa.2012-0640-OA. [DOI] [PubMed] [Google Scholar]
  • 90.Koss LG. Cytologic and histologic manifestations of human papillomavirus infection of the uterine cervix. Cancer Detect Prev. 1990;14:461–464. [PubMed] [Google Scholar]
  • 91.Rosai J. Ackerman's Surgical Pathology. In: St. Louis Mosby., editor. Rosai J. 1996. p. 1358. [Google Scholar]
  • 92.Joanna R, Renata Z, Witold P, Małgorzata S, Bernaczyk P, Chyczewski L. The evaluation of human papillomavirus and p53 gene mutation in benign and malignant conjunctiva and eyelid lesions. Folia Histochem Cytobiol. 2010;48:530–533. doi: 10.2478/v10042-010-0081-4. [DOI] [PubMed] [Google Scholar]
  • 93.Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol. 2005;32(Suppl 1):S1–S6. doi: 10.1016/j.jcv.2004.10.021. [DOI] [PubMed] [Google Scholar]
  • 94.Kayat KV, Correa Dantas PE, Felberg S, Galvão MA, Saieg MA. Exfoliative cytology in the diagnosis of ocular surface squamous neoplasms. Cornea. 2017;36:127–130. doi: 10.1097/ICO.0000000000001027. [DOI] [PubMed] [Google Scholar]
  • 95.Ip MH, Coroneo MT. Treatment of previously refractory ocular surface squamous neoplasia with topical cidofovir. JAMA Ophthalmol. 2017;135:500–502. doi: 10.1001/jamaophthalmol.2017.0365. [DOI] [PubMed] [Google Scholar]
  • 96.Ip MH, Robert George CR, Naing Z, Perlman EM, Rawlinson W, Coroneo MT. Topical cidofovir for treatment-refractory ocular surface squamous neoplasia. Ophthalmology. 2018;125:617–619. doi: 10.1016/j.ophtha.2017.11.021. [DOI] [PubMed] [Google Scholar]
  • 97.Bielamowicz S, Villagomez V, Stager SV, Wilson WR. Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope. 2002;112:696–699. doi: 10.1097/00005537-200204000-00019. [DOI] [PubMed] [Google Scholar]
  • 98.Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, Humphrey R, Pluda JM, Marshall V, Walters M, Welles L, et al. A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis. 2003;187:149–153. doi: 10.1086/346159. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Not applicable.


Articles from International Journal of Oncology are provided here courtesy of Spandidos Publications

RESOURCES